Biosimilar to Humira draws closer to commercialization

Boehringer Ingelheim announced today that adalimumab (BI 695501), biosimilar to AbbVie’s Humira, has been accepted to undergo the approval process by both EMA and FDA. Adalimumab is a monoclonal antibody that blocks mediators of inflammation TNF-α. The product is approved for the treatment of rheumatoid arthritis, psoriasis and other chronic inflammatory diseases.
(Source Boehringer Ingelheim)